Autolus Therapeutics PLC - American Depositary Shares (AUTL) closed at $1.19 on November 12, 2026, down 3.6% from the previous close, on volume of 2,480,367 shares (30-day average 2,245,614).
Data as of November 12, 2026.
TipRanks (Thu, 12-Nov 1:50 AM ET)
Wells Fargo Reaffirms Their Buy Rating on Autolus Therapeutics (AUTL)
TipRanks (Wed, 11-Nov 8:16 AM ET)
Globe Newswire (Tue, 10-Nov 4:05 PM ET)
Autolus Reports Strong Third-Quarter AUCATZYL Revenue Growth
TipRanks (Tue, 10-Nov 7:49 AM ET)
Autolus Therapeutics GAAP EPS of -$0.21 misses by $0.03, revenue of $41.24M beats by $1.21M
Seeking Alpha News (Tue, 10-Nov 7:12 AM ET)
Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Globe Newswire (Tue, 10-Nov 7:00 AM ET)
Here are the major earnings before the open Tuesday
Seeking Alpha News (Mon, 9-Nov 6:00 PM ET)
Autolus Therapeutics Q3 2026 Earnings Preview
Seeking Alpha News (Mon, 9-Nov 9:32 AM ET)
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference
Globe Newswire (Mon, 9-Nov 7:15 AM ET)
Alphabet maintains massive SpaceX bet, initiates $548M Qualcomm stake
Seeking Alpha News (Mon, 9-Nov 12:47 AM ET)
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
Autolus Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AUTL.
As of November 13, 2026, AUTL stock price declined to $1.18 with 429,255 million shares trading.
AUTL has a beta of 3.67, meaning it tends to be more sensitive to market movements. AUTL has a correlation of 0.36 to the broad based SPY ETF.
AUTL has a market cap of $313.79 million. This is considered a Small Cap stock.
Last quarter Autolus Therapeutics PLC - American Depositary Shares reported $41 million in Revenue and -$.21 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.03.
In the last 3 years, AUTL traded as high as $7.45 and as low as $1.11.
The top ETF exchange traded funds that AUTL belongs to (by Net Assets): IBB, CANC, GWX, QQQS, APIE.
AUTL has underperformed the market in the last year with a price return of -13.2% while the SPY ETF gained +10.9%. AUTL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -44.3% and -25.3%, respectively, while the SPY returned -2.6% and -2.5%, respectively.
AUTL support price is $1.14 and resistance is $1.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUTL shares will trade within this expected range on the day.
